MS Treatments React Differently to a COVID-19 vaccine
Are you being treated with a disease-modifying therapy (DMT) and wondering how it might impact the efficacy of an mRNA-based COVID-19 vaccine? If so, a recent study may provide some clarity. The study, published in Therapeutic Advances in Neurological Disorders, looked at 125 MS patients either being treated with Mavenclad (cladribine), Ocrevus (ocrelizumab), or Gilenya (fingolimod), or no DMT. A control group of healthy people also was included. Study participants…Continue Reading